Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Extended Half-Life (EHL) Clotting Factor for Improving the Musculoskeletal Health of Patients With Hemophilia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03914209
Recruitment Status : Not yet recruiting
First Posted : April 16, 2019
Last Update Posted : January 27, 2020
Sponsor:
Information provided by (Responsible Party):
Investigación en Hemofilia y Fisioterapia

Brief Summary:

Background. Hemophiliac arthropathy is the main long-term physical damage in patients with hemophilia, causing disability and functional limitations.

Objective. Assessment of the efficacy of a prophylactic treatment with EHL products for improving the musculoskeletal health of adult patients with hemophilia.

Study Design. Multicenter observational clinical study. Method. 40 patients with hemophilia A will be included in this study. Patients will be recruited from 5 centers located in various regions of Spain (Community of Madrid, Galicia, Community of Valenciana, Málaga and Vizcaya). The dependent variables will be: bleeding frequency (self-report of bleeding), changes in the dosage of factor VIII with EHL products (rFVIIIFc), pain (measured with the visual analog scale and a pressure Algometer), degree of kinesiophobia (Tampa Scale of Kinesiophobia), degree of adherence to treatment (Veritas-Pro scale), joint health (using the Hemophilia Joint Health Score), muscle strength (using a dynamometer) and functionality (using the 6-Minute Walking Test). Three evaluations will be carried out: baseline, at 6 months, and at the end of the study period, at 12 months. The evolution of quantitative variables shall be analyzed by parametric tests (t-student test) or non-parametric tests (Wilcoxon test). Pearson's correlation coefficient shall be used to obtain the correlation between the dependent and independent variables. By means of a linear regression analysis we will record the percentage influence of the clinical variables relative to the dependent variables measured in this study Expected results. The aim is to establish the effectiveness of the prophylactic treatment in the improvement of the state health, joint pain, muscle strength and functionality in patients with hemophilia.


Condition or disease Intervention/treatment
Haemophilia Other: EHL clotting factor

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Efficacy of a Prophylactic Treatment Using Extended Half-Life (EHL) Clotting Factor for Improving the Musculoskeletal Health of Adult Patients With Hemophilia. Observational Multicenter Study
Estimated Study Start Date : February 2, 2020
Estimated Primary Completion Date : November 10, 2020
Estimated Study Completion Date : December 15, 2020

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
EHL clotting factor
This study shall not implement any intervention that might alter the normal development of the daily life activities of hemophilia patients included in the study. They will continue with the prophylactic regimen prescribed by their hematologist. Patients will also be asked to continue to develop their physical, work, entertainment and leisure activities in the same way as at baseline.
Other: EHL clotting factor
This study shall not implement any intervention that might alter the normal development of the daily life activities of hemophilia patients included in the study. They will continue with the prophylactic regimen prescribed by their hematologist. Patients will also be asked to continue to develop their physical, work, entertainment and leisure activities in the same way as at baseline.




Primary Outcome Measures :
  1. Change from baseline bleeding frequency after one year of follow-up [ Time Frame: Screening visit, at six months and after one year of follow-up ]
    At baseline, patients will receive a personal self-report of bleeding (hematomas, hemarthrosis and mucous hemorrhagic episodes) where they should indicate the frequency of bleeding during the study period. This record should be delivered to the evaluators in the intermediate assessment and the final evaluation. In this way, changes in the frequency of bleeding throughout the study period will be evaluated


Secondary Outcome Measures :
  1. Change from baseline dosage of factor VIII with EHL products after one year of follow-up [ Time Frame: Screening visit, at six months and after one year of follow-up ]
    Changes in the dosage of factor VIII with EHL products (rFVIIIFc) during the study period will be included in all assessments. Dosing data (UI) and weekly administration frequency (days / week) will be collected.

  2. Change from baseline joint pain after one year of follow-up [ Time Frame: Screening visit, at six months and after one year of follow-up ]
    Visual analog scale. This scale will be used to evaluate the perception of joint pain, where joint pain ranges from 0 to 10 points (no pain to maximum perceived pain).

  3. Change from baseline joint pain after one year of follow-up: Pressure algometer [ Time Frame: Screening visit, at six months and after one year of follow-up ]
    Pressure algometer. Measuring instrument used to evaluate pressure joint pain. The instrument shall consist of a measuring device attached to a hard rubber tip 1.1 cm in diameter. Its sphere shall be calibrated in kg/cm2 with divisions of 0.1 kg/cm2. Before taking the measurements, patients will be instructed to say "yes" as soon as pressure exerted by the algometer becomes slightly unpleasant. The pressure algometer shall be kept perpendicular to the surface of the skin with the right hand, stabilizing the axis of the instrument using the thumb and index finger of the left hand. The pressure shall be increased at a uniform rate of approximately 1 kg/cm2 per second. As soon as the subject, according to the instructions, says "yes", the pressure will be stopped and the score will be noted.

  4. Change from baseline kinesiophobia after one year of follow-up [ Time Frame: Screening visit, at six months and after one year of follow-up ]
    Tampa Scale of Kinesiophobia (TSK-11SV). This questionnaire will be used to assess the fear of movement in study patients. It consists of 11 items and the values range from 1 to 4 points (the higher the score, the greater the fear of movement).

  5. Change from baseline joint status after one year of follow-up [ Time Frame: Screening visit, at six months and after one year of follow-up ]
    Hemophilia Joint Health Score (HJHS). This measuring instrument will be used to evaluate the joint condition of knees, ankles, and elbows. It includes 8 items (inflammation and its duration, pain, atrophy and muscle strength, crepitus, and reduced flexion and extension) ranging from 0 to 20 points per joint (the higher the score, the greater the joint deterioration).

  6. Change from baseline lower limb functionality after one year of follow-up [ Time Frame: Screening visit, at six months and after one year of follow-up ]
    6-Minute Walking test (6-MWT). The 6-MWT test is a performance-based test that measures walking speed and the submaximal capacity to perform an exercise. Patients are instructed to walk along a 30 to 50-meter track for 6 minutes attempting to cover as much distance as possible without running. The distance traveled in 6 minutes is recorded, allowing the use of a walking aid or orthopedic devices.

  7. Change from baseline muscle strength after one year of follow-up [ Time Frame: Screening visit, at six months and after one year of follow-up ]
    Dynamometry. The maximum isometric strength of the flexor and extensor muscles of the main joints affected in hemophilia (knees, ankles, and elbows) will be evaluated on both limbs with a manual dynamometer using a mark test. For this test, the rater needs to keep the dynamometer stationary while the patient exerts maximum force against it.

  8. Change from baseline adherence to prophylactic treatment after one year of follow-up [ Time Frame: Screening visit, at six months and after one year of follow-up ]
    Veritas-Pro. Specific adhesion questionnaire for hemophilia patients receiving prophylactic treatment. The Validated Hemophilia Regimen Treatment Adherence Scale - Prophylaxis (Veritas-Pro) questionnaire was developed in the United States and has already been validated in Spanish. The Veritas-Pro scale consists of 24 Likert-type items from 1 to 5, grouped in five dimensions: Time, Dose, Plan, Remembering, Skip and Communicate. The minimum adherence score is 24 points and the maximum adherence score is 120, and in each sub-scale the score ranges from 4 and 20 points.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

The sample size is justified in relation to the prevalence of hemophilia A patients in Spain following prophylactic treatment based on EHL products. Based on the established selection criteria (n = 517, according to the census of the Spanish Federation of Hemophilia), the sample size at the national level would be 146, with a confidence or safety level of 95% and an expected dropout rate of 15%.

Currently in Spain, treatment with EHL products (rFVIIIFc) in patients with hemophilia A is being implemented and generalized. Thus, for the 8 Spanish regions where the study will be carried out, a sample of 40 patients is established for the work schedule set.

Criteria

Inclusion Criteria:

  • Patients diagnosed with hemophilia A
  • Patients over 18 years
  • Patients under prophylactic treatment with rFVIIIFc concentrates.

Exclusion Criteria:

  • Patients with neurological or cognitive disorders preventing the understanding of the various measuring instruments
  • Patients who are scheduled for major orthopedic surgery (total arthroplasty)
  • Not signed the Informed Consent Document

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03914209


Contacts
Layout table for location contacts
Contact: Rubén Cuesta-Barriuso, PhD +34 607547274 ruben.cuestab@gmail.com

Locations
Layout table for location information
Spain
Universidad Europea de Madrid
Madrid, Comunity Of Madrid, Spain, 28670
Sponsors and Collaborators
Investigación en Hemofilia y Fisioterapia
Investigators
Layout table for investigator information
Principal Investigator: Rubén Cuesta-Barriuso, PhD Universidad Europea de Madrid
Layout table for additonal information
Responsible Party: Investigación en Hemofilia y Fisioterapia
ClinicalTrials.gov Identifier: NCT03914209    
Other Study ID Numbers: LongHEst
First Posted: April 16, 2019    Key Record Dates
Last Update Posted: January 27, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn